Transforming Neuropsychiatric Care with First- and Best-in-Class Science

The M4 muscarinic receptor is a validated target for treating schizophrenia and related disorders through indirect modulation of dopamine signaling. NTX-253 is a potent, selective, oral positive allosteric modulator (PAM) of M4 that fine-tunes muscarinic signaling with the potential to reduce psychosis symptoms while avoiding the movement disorders and metabolic complications associated with traditional dopamine antagonists. Preclinical studies demonstrate robust antipsychotic-like activity and a favorable safety profile, supporting advancement into first-in-human clinical trials planned for late 2025.

The metabotropic glutamate receptor 7 (mGlu7) is an emerging target for mood and anxiety disorders, with strong links to brain circuits implicated in stress, agitation, and anhedonia. NTX-819 is a first-in-class, oral negative allosteric modulator (NAM) of mGlu7 that modulates glutamatergic signaling to restore balance in these circuits. Preclinical studies demonstrate robust anxiolytic- and antidepressant-like activity with a favorable safety profile, supporting its development as a potential next-generation therapy where current treatments often fall short.